● Recruiting

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Condition: ER+, HER 2- Breast Cancer · Non-small Cell Lung Cancer (NSCLC) · Castration-resistant Prostate Cancer (CRPC) · Sponsor: IDEAYA Biosciences

PhasePhase 1

Planned participants160

Who can joinAll sexes, 18 Years to 99 Years

Healthy volunteersNo

About this study

IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic ER+, HER2- breast cancer.

This description comes directly from the study's public registry record.

Talk to the study team

IDEAYA Clinical Trials · +1-855-433-224 · IDEAYAClinicalTrials@ideayabio.com

Always discuss trial participation with your own doctor first.

Locations (11)

Florida Clinical Trials Group	Plantation, Florida, United States	Recruiting
START Astera, LLC	East Brunswick, New Jersey, United States	Recruiting
START New York Long Island, LLC	Lake Success, New York, United States	Recruiting
NEXT Texas LLC - Austin	Austin, Texas, United States	Recruiting
NEXT Texas LLC - Dallas	Dallas, Texas, United States	Recruiting
START Dallas Fort Worth, LLC	Fort Worth, Texas, United States	Recruiting
NEXT Texas LLC - Houston	Houston, Texas, United States	Recruiting
NEXT Texas LLC - San Antonio	San Antonio, Texas, United States	Recruiting
Start San Antonio, LLC	San Antonio, Texas, United States	Recruiting
START Mountain Region, LLC	West Valley City, Utah, United States	Recruiting
NEXT Virginia	Fairfax, Virginia, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07540572